Repository logo
 
Publication

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome

2021-02Journal article Open access
Simple item page
dc.contributor.authorMarques, Joao Heitor
dc.contributor.authorAbreu, Ana Carolina
dc.contributor.authorSilva, Nisa
dc.contributor.authorMeireles, Angelina
dc.contributor.authorPessoa, Bernardete
dc.contributor.authorBeirão, João
dc.date.accessioned2023-10-23T11:28:12Z
dc.date.available2023-10-23T11:28:12Z
dc.date.issued2021-02
dc.description.abstractBackground: Cystoid macular edema (CME) due to Irvine-Gass syndrome (IGS) is one of the common causes of painless visual impairment post-cataract extraction. The treatment of recurrent cases remains unstandardized. Objective: To evaluate the effectiveness and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day; ILUVIEN®) in the off-label treatment of recurrent CME due to IGS. Methods: Retrospective 36-month case series in the Ophthalmology Department of Centro Hospitalar Universitário do Porto, Portugal. Consecutive eyes of patients with recurrent cystoid macular edema due to Irvine-Gass syndrome who underwent a single intravitreal injection of fluocinolone acetonide intravitreal implant were included. Best-corrected visual acuity (logMAR), central macular thickness (µm) and safety (intraocular pressure, mmHg) at baseline and at 6, 12, 24 and 36 months post-administration of the fluocinolone acetonide intravitreal implant were recorded. Results: Five eyes from three patients were included. The duration of cystoid macular edema was 67.8±25.9 months and all five eyes received more than 2 intravitreal injections of a corticosteroid (triamcinolone and/or dexamethasone implant) prior to fluocinolone acetonide intravitreal implantation. At baseline (median - interquartile range), best-corrected visual acuity was 0.3-0.3; central macular thickness was 492.0-38.0; and intraocular pressure was 16.0-0. By Month 36, best-corrected visual acuity was 0.4 -0.3; central macular thickness was reduced to 369.0-324.0 and intraocular pressure was 17.0-3.0. Four of five eyes had increased intraocular pressure and were managed with intraocular pressure-lowering eye drops. Conclusion: We report improved functional and anatomical outcomes after treatment with fluocinolone acetonide intravitreal implant, indicating its use as a therapeutic alternative in recurrent cases of cystoid macular edema due to Irvine-Gass syndrome. Additionally, in eyes with suboptimal response to intravitreal therapies, fluocinolone acetonide intravitreal implant may provide longer recurrence-free periods with reduced treatment burden.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMarques JH, Abreu AC, Silva N, Meireles A, Pessoa B, Melo Beirão J. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome. Int Med Case Rep J. 2021;14:127-132. doi:10.2147/IMCRJ.S295045pt_PT
dc.identifier.doi10.2147/IMCRJ.S295045pt_PT
dc.identifier.issn1179-142X
dc.identifier.urihttp://hdl.handle.net/10400.16/2833
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherDove Medical Presspt_PT
dc.relation.publisherversionhttps://www.dovepress.com/fluocinolone-acetonide-019-mg-implant-in-patients-with-cystoid-macular-peer-reviewed-fulltext-article-IMCRJpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectIrvine–Gass syndromept_PT
dc.subjectcataract surgerypt_PT
dc.subjectcystoid macular edemapt_PT
dc.subjectfluocinolone acetonidept_PT
dc.subjectpseudophakic cystoid macular edemapt_PT
dc.titleFluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndromept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceNew Zealandpt_PT
oaire.citation.endPage132pt_PT
oaire.citation.startPage127pt_PT
oaire.citation.titleInternational Medical Case Reports Journalpt_PT
oaire.citation.volume14pt_PT
person.familyNameMarques
person.familyNameAbreu
person.familyNameSilva
person.familyNameMeireles
person.familyNamePessoa
person.familyNameBeirão
person.givenNameJoao Heitor
person.givenNameAna Carolina
person.givenNameNisa
person.givenNameAngelina
person.givenNameBernardete
person.givenNameJoão Nuno Melo
person.identifier.ciencia-id0E1B-7EB2-B90F
person.identifier.ciencia-id0214-5233-EE9D
person.identifier.orcid0000-0001-6487-7950
person.identifier.orcid0000-0003-4842-8623
person.identifier.orcid0000-0002-5607-3212
person.identifier.orcid0000-0001-9148-2786
person.identifier.orcid0000-0002-5673-1561
person.identifier.orcid0000-0001-8642-7010
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb1e9a3af-258b-4e7c-9ea6-bb2f67e31bfd
relation.isAuthorOfPublicationeab24879-bc6b-47e8-8c97-fb00e822e7e9
relation.isAuthorOfPublicationec9dd182-1d5c-459f-a034-0a14abed937e
relation.isAuthorOfPublication8832627a-5103-43bb-a479-6556c8b18d44
relation.isAuthorOfPublicationfa0e3b13-5da3-4f74-a184-22358fc19d38
relation.isAuthorOfPublication03b98348-ce82-4043-bb58-db089fcc21d6
relation.isAuthorOfPublication.latestForDiscoveryb1e9a3af-258b-4e7c-9ea6-bb2f67e31bfd

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Marques-2021-Fluocinolone-acetonide--mg-implant-.pdf
Size:
2.47 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SOFT - Artigos publicados em revistas indexadas na Pubmed/Medline